Clinical Trials Sponsored by Henan Oncology Hospital

Total 1033 results

Henan Cancer Hospital

Not yet recruiting

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Metastatic Colon Cancer
Henan Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Henan Cancer Hospital

Recruiting

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Squamous Cell Carcinoma of the Skin

China
Henan Cancer Hospital

Recruiting

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Henan Cancer Hospital

Not yet recruiting

Application of Antiosteoporosis Therapy in Osteolysis

Complication | Limb; Fusion

China
Henan Cancer Hospital

Not yet recruiting

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Gastric Cancer | Gastroesophageal-junction Cancer
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Henan Cancer Hospital

Not yet recruiting

A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients

Early Gastric Cancer | Tumor Organoids
Henan Cancer Hospital

Recruiting

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Breast Cancer

China
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital

Recruiting

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Henan Cancer Hospital

Not yet recruiting

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction
Henan Cancer Hospital

Recruiting

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Chemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric Carcinoma

China
Henan Cancer Hospital

Recruiting

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Henan Cancer Hospital

Recruiting

A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

Digestive System Tumors

China
Henan Cancer Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

China
Henan Cancer Hospital

Recruiting

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Esophageal Cancer | Surgery | Survival | Neoadjuvant Treatment

China
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
Henan Cancer Hospital

Active, not recruiting

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer

China
Henan Cancer Hospital

Completed

Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma

Esophagus Cancer

China
Henan Cancer Hospital

Completed

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Henan Cancer Hospital

Unknown

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Lung Adenocarcinoma

China
Henan Cancer Hospital

Unknown

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Advanced Solid Tumor

China
Henan Cancer Hospital

Unknown

An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment

Cancer

China
Henan Cancer Hospital

Withdrawn

Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer

Esophageal Cancer | Lung Cancer | Hyperthermic Perfusion

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital

Unknown

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

HER2 Positive Breast Cancer
Henan Cancer Hospital

Unknown

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

The Maintenance Treatment of "ITIVA" in AML Patients

Acute Myeloid Leukemia | Thalidomide | Maintenance Treatment | Minor Residue Disease | Interferon-α-1b | Interleukin-2 | Venentoclax | Azacitidine

China
Henan Cancer Hospital

Not yet recruiting

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Advanced Breast Cancer | Treatment | HR Low/HER2 Negative
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Henan Cancer Hospital

Recruiting

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

Sexuality | Effectiveness

China
Henan Cancer Hospital

Not yet recruiting

Application of LARS Ligament in Bone Prosthesis Replacement

Malignant Tumor

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Henan Cancer Hospital

Recruiting

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Desmoid

China
Henan Cancer Hospital

Recruiting

Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Clinical Features | Bone and Soft Tissue Tumors

China
Henan Cancer Hospital

Recruiting

PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

Advanced Melanoma

China
Henan Cancer Hospital

Recruiting

Study on Clinical Features, Treatment Mode and Survival of Sarcoma

Sarcoma

China
Henan Cancer Hospital

Recruiting

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

SCLC, Extensive Stage

China
Henan Cancer Hospital

Not yet recruiting

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. (SCRCA)

Cholangiocarcinoma
Henan Cancer Hospital

Recruiting

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Soft Tissue Sarcoma

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Henan Cancer Hospital

Recruiting

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Marginal Zone Lymphoma

China
Henan Cancer Hospital

Recruiting

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Lymphoma | Gene Abnormality

China

3

Subscribe